Drug Trial Radar · NCT07354022
A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
912
Planned (sponsor's estimate)
Start
May 5, 2026
Primary completion
Dec 2028
Study completion Dec 2031
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.
Conditions
- Locally Advanced or Metastatic Breast Cancer
Interventions
HRS-8080 Tablet ; Dalpiciclib IsethionateDrug
* HRS-8080 Tablet * Dalpiciclib Isethionate
Fulvestrant injection ;Dalpiciclib IsethionateDrug
* Fulvestrant injection * Dalpiciclib Isethionate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator assessed Progression free survival (PFS)Time frame: Up to 5 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital Fifth Medical Center
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.